Skip to main content

Table 1 RECK and EMMPRIN staining in renal cell tumors related to clinicopathological parameters

From: Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis

Variable

Cases (n / %)

RECK expression (number of cases / %)

P value*

  

0

1

2

3

 

Age

≤60 years

197 (49.9)

161 (81.7)

27 (13.7)

8 (4.1)

1 (0.5)

0.580

 

>60 years

198 (50.1)

164 (82.8)

22 (11.1)

5 (2.5)

7 (3.5)

 

Sex

male

264 (66.8)

212 (80.3)

36 (13.6)

11 (4.2)

5 (1.9)

0.234

 

female

131 (33.2)

113 (86.3)

13 (9.9)

2 (1.5)

3 (2.3)

 

pT status

pT1-2

265 (67.1)

216 (81.5)

32 (12.1)

10 (3.8)

7 (2.6)

0.250

 

pT3-4

130 (32.9)

109 (83.8)

17 (13.1)

3 (2.3)

1 (0.8)

 

Fuhrman grade

1-2

348 (88.1)

285 (81.9)

43 (12.4)

12 (3.4)

8 (2.3)

0.338

 

3-4

47 (11.9)

40 (85.1)

6 (12.8)

1 (2.1)

0 (0.0)

 

Nodal status**

pN0

214 (89.9)

182 (85.0)

25 (11.7)

5 (2.3)

2 (0.9)

0.878

 

pN+

24 (10.1)

20 (83.3)

3 (12.5)

1 (4.2)

0 (0.0)

 

Metastases***

M0

338 (90.6)

278 (82.2)

41 (12.1)

12 (3.6)

7 (2.1)

0.300

 

M1

35 (9.4)

31 (88.6)

3 (8.6)

1 (2.9)

0 (0.0)

 

Margin status****

R0

357 (94.4)

291 (81.5)

46 (12.9)

12 (3.4)

8 (2.2)

0.603

 

R+

21 (5.6)

18 (85.7)

2 (9.5)

1 (4.8)

0 (0.0)

 

Tumor subtype

       

  Clear cell RCC

 

322 (81.5)

291 (90.4)

27 (8.4)

3 (0.9)

1 (0.3)

<0.001

  Papillary RCC

 

43 (10.9)

23 (53.5)

11 (25.6)

8 (18.6)

1 (2.3)

 

  Chromophobe RCC

 

22 (5.6)

10 (45.5)

7 (31.8)

1 (4.5)

4 (18.2)

 

  Oncocytoma

 

8 (2.0)

1 (12.5)

4 (50.0)

1 (12.5)

2 (25.0)

 
   

EMMPRIN expression (number of cases / %)

 
   

0

1

2

3

 

Age

≤60 years

196 (49.7)

7 (3.6)

57 (29.1)

70 (35.7)

62 (31.6)

0.479

 

>60 years

198 (50.3)

8 (4.0)

54 (27.3)

87 (43.9)

49 (24.7)

 

Sex

male

263 (66.8)

13 (4.9)

70 (26.6)

102 (38.8)

78 (29.7)

0.797

 

Female

131 (33.2)

2 (1.5)

41 (31.3)

55 (42.0)

33 (25.2)

 

pT status

pT1-2

265 (67.3)

14 (5.3)

86 (32.5)

112 (42.3)

53 (20.0)

<0.001

 

pT3-4

129 (32.7)

1 (0.8)

25 (19.4)

45 (34.9)

58 (45.0)

 

Fuhrman grade

1-2

347 (88.1)

15 (4.3)

109 (31.4)

141 (40.6)

82 (23.6)

<0.001

 

3-4

47 (11.9)

0 (0.0)

2 (4.3)

16 (34.0)

29 (61.7)

 

Nodal status**

pN0

213 (89.9)

6 (2.8)

63 (29.6)

78 (36.6)

66 (31.0)

0.003

 

pN+

24 (10.1)

1 (4.2)

1 (4.2)

7 (29.2)

15 (62.5)

 

Metastases***

M0

337 (90.6)

15 (4.5)

101 (30.0)

138 (40.9)

83 (24.6)

<0.001

 

M1

35 (9.4)

0 (0.0)

6 (17.1)

9 (25.7)

20 (57.1)

 

Margin status****

R0

356 (94.4)

15 (4.2)

105 (29.5)

145 (40.7)

91 (25.6)

0.004

 

R+

21 (5.6)

0 (0.0)

3 (14.3)

6 (28.6)

12 (57.1)

 

Tumor subtype

      

  Clear cell RCC

322 (81.7)

9 (2.8)

91 (28.3)

128 (39.8)

94 (29.2)

0.813

  Papillary RCC

42 (10.7)

6 (14.3)

14 (33.3)

16 (38.1)

6 (14.3)

 

  Chromophobe RCC

22 (5.6)

0 (0.0)

5 (22.7)

9 (40.9)

8 (36.4)

 

  Oncocytoma

8 (2.0)

0 (0.0)

1 (12.5)

4 (50.0)

3 (37.5)

 
  1. *Chi-square test using linear-by-linear association, significant P values <0.05 are given in bold. **157 cases were pNx or not assessed, pN+ includes all N-positive cases. ***22 cases were Mx or not assessed. ****17 cases were Rx.